UCSF San Francisco
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Matthay, Michael A
ACTIV-4, NCT04505774 / 2020-004285-19: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Completed
4
3591
Europe, US, RoW
theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin
Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI)
Covid19
08/23
01/24
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting
3
970
US
ExoFlo, Intravenous normal saline
Direct Biologics, LLC
Acute Respiratory Distress Syndrome, ARDS
03/25
08/25
STAT, NCT03818854: Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

Completed
2
120
US
Human Mesenchymal Stromal Cells, hMSCs, Cell Reconstitution Media, Placebo
Michael A. Matthay, United States Department of Defense, Harborview Injury Prevention and Research Center, Oregon Health and Science University, Vanderbilt University Medical Center, The University of Texas Health Science Center, Houston, University of Minnesota
Respiratory Distress Syndrome, Adult
03/24
06/24

Download Options